The capacity to distinguish tumors that will benefit from anti-cancer treatments from those that will not remains a challenge. Patient-derived xenografts (PDXs), also called “avatars,” are generated by the implantation of human primary tumor cells or tissues into a host animal.
Many PDX models have been developed to be used as a platform for drug screening in cancer research and precision medicine, mainly using mouse models. However, mouse models require a long time for tumor growth, which is not compatible with first clinical decisions.
